Skip to content
ViqusViqus
Navigate
Company
Blog
About Us
Contact
System Status
Enter Viqus Hub

Max Hodak's Science Corp Raises $400M, Valued at $3.5B for Brain Tech

Brain-Computer Interface MedTech Implantable Chip Series D Macular Degeneration Neuralink
November 17, 2026
Source: TechCrunch AI

This summary and analysis were generated by AI from the original article at TechCrunch AI and may contain errors (how Viqus works). Read the source for full details.

Viqus Verdict Logo Viqus Verdict Logo 7
High-Stakes BCI Validation
Media Hype 5/10
Real Impact 7/10

Article Summary

Science Corporation, established by Max Hodak, announced a successful $400 million Series D funding round, which valued the medical technology startup at $3.5 billion. The company's initial product, PRIMA, is a wearable and implantable chip for age-related macular degeneration, already approved in Europe. With this capital, Science plans to pursue FDA approval in the US for rare conditions. Beyond vision restoration, the company's long-term goal involves developing a bio-hybrid sensor connecting directly to the human brain, with ongoing trials exploring applications for conditions like Parkinson's disease.

Key Points

  • Science Corporation raised $400 million in Series D funding, achieving a $3.5 billion valuation.
  • The company's near-term focus is bringing its PRIMA chip, for macular degeneration, to the US via FDA exemption.
  • The long-term vision involves developing a bio-hybrid sensor for direct brain-computer interface applications, including Parkinson's research.

Why It Matters

This funding round validates the high-risk, high-reward nature of direct neural interface technology. While the immediate focus on vision restoration is incremental, the underlying ambition—a bio-hybrid sensor for brain connection—represents a significant, albeit distant, step toward true BCI, keeping it in the high-impact category for long-term monitoring.


You might also be interested in